electroCore ^{Priced, Nasdaq: ECOR}

We are a commercial-stage bioelectronic medicine company with a non-invasive vagus nerve stimulation therapy initially focused on neurology and rheumatology. Our therapy, gammaCore, has pharmacologic effects on the peripheral and central nervous systems, which modulate neurotransmitters and immune function. gammaCore is FDA-cleared for the acute treatment of pain associated with migraine and episodic cluster headache. Based on our clinical data, we are pursuing label expansions for the prevention of migraine, migraine in adolescents and post-traumatic headache, and are also engaging in clinical development for potential new labeling claims in rheumatology, including Sjôgren's syndrome and rheumatoid arthritis. Following our initial FDA clearance in April 2017, our commercial strategy has been to establish gammaCore as a first-line treatment option for episodic cluster headache patients, who have few alternative treatment options available to them. Given our limited resources, we chose to enter the market with a targeted product registry that prioritized early development of advocacy and reimbursement to best position us for commercial launch in the US in the 3Q18. In January 2018, we received FDA clearance for gammaCore for the acute treatment of pain associated with migraine headaches.